This three-month prospective, openlabel, randomized, controlled trial was conducted to investigate whether oral supplementation of resveratrol would improve glycemic control and the associated risk factors in patients with type 2 diabetes mellitus (T2DM). Sixty-two patients with T2DM were randomized into control and intervention groups whereby the control group received only oral hypoglycemic agents and the intervention group received resveratrol (250 mg/d) along with their oral hypoglycemic agents. Hemoglobin A(1c) (HBA1c), lipid profile, urea nitrogen, creatinine, and protein were measured at baseline and again at the end of three months. Results revealed that supplementation of resveratrol significantly improved mean HBA1c (9.99 ± 1.50 vs 9.65 ± 1.54; P < 0.05), mean systolic blood pressure (139.71 ± 16.10 vs 127.92 ± 15.37; P <0 .05), mean total cholesterol (4.70 ± 0.90 vs 4.33 ± 0.76; P <0 .05), and mean total protein (75.6 ± 4.6 vs 72.3 ± 6.2; P < 0.05) in T2DM. No significant changes in body weight, high-density lipoprotein, and low-density lipoprotein cholesterols were observed. These results suggest that resveratrol may possibly provide a potential adjuvant for the treatment and management of diabetes. Nutr Res. 2012 Jul;32(7):537-41. PMID: 22901562
